AIM AIM ImmunoTech Inc.
Price Chart
Executive Summary
AIM ImmunoTech closed a warrant exercise inducement transaction on May 8, 2026, receiving ~$3.6M in gross proceeds from the cash exercise of 7,451,920 existing warrants at a reduced price of $0.48/share. In exchange, the company issued new Class H warrants to purchase up to 14,903,840 shares at $0.60/share, plus placement agent warrants for 894,230 shares at $0.60/share. This is a dilutive capital raise for a micro-cap company with a $3M market cap, providing near-term cash but massively increasing potential share count.
Key Financial Metrics
Actionable Insight
The $3.6M injection provides short-term liquidity for a micro-cap with a $3M market cap, but the potential dilution from up to 15.8M new warrants (exercisable at $0.60) is enormous relative to current shares outstanding. Monitor for stockholder approval of the warrants and any subsequent exercise. The reduced exercise price of $0.48 for existing warrants suggests existing holders were unwilling to exercise at higher levels, signaling weak conviction in the stock's value.
Key Facts
- Closed inducement transaction on May 8, 2026
- Received aggregate gross proceeds of approximately $3.6 million
- Holders exercised existing warrants for 7,451,920 shares at $0.48 per share (reduced exercise price)
- Issued new Class H warrants to purchase up to 14,903,840 shares at $0.60 per share
- Issued placement agent warrants to purchase 894,230 shares at $0.60 per share
- Placement agent received ~$285,000 cash fee (8.0% of gross proceeds), $50,000 expenses, and ~$26,000 management fee
- New warrants have 5-year term, exercisable after stockholder approval
- Placement agent warrants have exercise price equal to 125% of the reduced exercise price ($0.60)
- Company market cap is only ~$3M, making the potential dilution from new warrants extremely significant
Financial Impact
Gross proceeds of ~$3.6M from cash exercise of 7.45M shares at $0.48/share. Potential future dilution from up to 15.8M new warrants (14.9M Class H + 0.89M placement agent) at $0.60/share, which is massive relative to a $3M market cap.
Risk Factors
- Massive potential dilution from up to 15.8M new warrants relative to current ~$3M market cap
- Reduced exercise price ($0.48) indicates existing warrant holders needed a discount to exercise
- Company is pre-revenue biotech with no approved products, relying on dilutive financing
- Placement agent warrants with piggyback registration rights could lead to accelerated selling pressure
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022499 |
| Document: form8-k.htm | 0001493152-26-022499 |
| Document: 0001493152-26-022499-index-headers.html | 0001493152-26-022499 |
| Document: 0001493152-26-022499-index.html | 0001493152-26-022499 |
| Document: 0001493152-26-022499.txt | 0001493152-26-022499 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
Press Release
| $0.4589 awaiting T+1 | awaiting T+1 | — | $0.5200 (+13.31%) |
|
Jun 4, 2026
5d ago
|
8-K
| $0.5900 $0.5200 | ▼ −11.86% | ▼ −9.27% | $0.5200 (−11.86%) |
|
Jun 1, 2026
8d ago
|
Press Release
| $0.9000 $0.8300 | ▼ −7.78% | ▼ −7.92% | $0.5200 (−42.22%) |
|
May 21, 2026
19d ago
|
8-K
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.5200 (−116.67%) |
|
May 21, 2026
19d ago
|
424B5
| $0.2400 $0.2400 | · 0.00% | ▲ +0.45% | $0.5200 (−116.67%) |
|
May 20, 2026
20d ago
|
Press Release
| $0.2500 $0.2400 | ▲ +4.00% | ▲ +4.19% | $0.5200 (−108.00%) |
|
May 19, 2026
21d ago
|
424B5
| $0.2500 $0.2400 | ▼ −4.00% | ▼ −4.19% | $0.5200 (+108.00%) |
|
May 19, 2026
21d ago
|
8-K
| $0.4100 $0.2500 | ▼ −39.02% | ▼ −40.06% | $0.5200 (+26.83%) |
|
May 14, 2026
26d ago
|
8-K
| $0.2600 $0.2500 | ▼ −3.85% | ▼ −2.62% | $0.5200 (+100.00%) |
|
May 14, 2026
26d ago
|
Press Release
| $0.2600 $0.2500 | ▼ −3.85% | ▼ −2.62% | $0.5200 (+100.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access